BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31117253)

  • 21. Apoptotic Effect of Galbanic Acid via Activation of Caspases and Inhibition of Mcl-1 in H460 Non-Small Lung Carcinoma Cells.
    Oh BS; Shin EA; Jung JH; Jung DB; Kim B; Shim BS; Yazdi MC; Iranshahi M; Kim SH
    Phytother Res; 2015 Jun; 29(6):844-9. PubMed ID: 25753585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells.
    Park SH; Lee DH; Kim JL; Kim BR; Na YJ; Jo MJ; Jeong YA; Lee SY; Lee SI; Lee YY; Oh SC
    Oncotarget; 2016 Sep; 7(37):59503-59518. PubMed ID: 27517746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
    Zarogoulidis P; Petanidis S; Kioseoglou E; Domvri K; Anestakis D; Zarogoulidis K
    Cell Signal; 2015 Aug; 27(8):1576-88. PubMed ID: 25917317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel c-Myc-Targeting Compound
    Sriratanasak N; Petsri K; Laobuthee A; Wattanathana W; Vinayanuwattikun C; Luanpitpong S; Chanvorachote P
    Mol Pharmacol; 2020 Aug; 98(2):130-142. PubMed ID: 32487733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renieramycin M Sensitizes Anoikis-resistant H460 Lung Cancer Cells to Anoikis.
    Sirimangkalakitti N; Chamni S; Suwanborirux K; Chanvorachote P
    Anticancer Res; 2016 Apr; 36(4):1665-71. PubMed ID: 27069144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target Identification of 22-(4-Pyridinecarbonyl) Jorunnamycin A, a Tetrahydroisoquinoline Derivative from the Sponge
    Iksen I; Sinsook S; Wattanathamsan O; Buaban K; Chamni S; Pongrakhananon V
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36558080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.
    Koo J; Yue P; Deng X; Khuri FR; Sun SY
    Mol Cell Biol; 2015 Jul; 35(13):2344-55. PubMed ID: 25918246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polypeptide antibiotic actinomycin D induces Mcl-1 uncanonical downregulation in lung cancer cell apoptosis.
    Chen CL; Tseng PC; Chao YP; Shen TJ; Jhan MK; Wang YT; Nguyen TT; Lin CF
    Life Sci; 2023 May; 321():121615. PubMed ID: 37001403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monosaccharide digitoxin derivative sensitize human non-small cell lung cancer cells to anoikis through Mcl-1 proteasomal degradation.
    Pongrakhananon V; Stueckle TA; Wang HL; O'Doherty GA; Dinu CZ; Chanvorachote P; Rojanasakul Y
    Biochem Pharmacol; 2014 Mar; 88(1):23-35. PubMed ID: 24231508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemistry of Renieramycins. 17. A New Generation of Renieramycins: Hydroquinone 5-O-Monoester Analogues of Renieramycin M as Potential Cytotoxic Agents against Non-Small-Cell Lung Cancer Cells.
    Chamni S; Sirimangkalakitti N; Chanvorachote P; Saito N; Suwanborirux K
    J Nat Prod; 2017 May; 80(5):1541-1547. PubMed ID: 28459574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
    Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
    Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
    Fan F; Tonon G; Bashari MH; Vallet S; Antonini E; Goldschmidt H; Schulze-Bergkamen H; Opferman JT; Sattler M; Anderson KC; Jäger D; Podar K
    Cancer Lett; 2014 Feb; 343(2):286-94. PubMed ID: 24120758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC.
    Ma J; Zhao Z; Wu K; Xu Z; Liu K
    Gene; 2016 Aug; 587(2):147-54. PubMed ID: 27138804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells.
    Lin L; Ding D; Xiao X; Li B; Cao P; Li S
    J Cell Mol Med; 2020 Jun; 24(12):6822-6832. PubMed ID: 32352219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
    Williams MM; Lee L; Werfel T; Joly MMM; Hicks DJ; Rahman B; Elion D; McKernan C; Sanchez V; Estrada MV; Massarweh S; Elledge R; Duvall C; Cook RS
    Cell Death Dis; 2018 Jan; 9(2):21. PubMed ID: 29343814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and development of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as Bcl-2/Mcl-1 inhibitors.
    Liu R; Liu L; Yang X; Fang H
    Bioorg Chem; 2019 Jul; 88():102938. PubMed ID: 31028992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.